American Society of Hematology, Blood, 14(131), p. 1576-1586
DOI: 10.1182/blood-2017-07-798157
Full text: Unavailable
Key Points Targetable ALK/ROS1 tyrosine kinase fusions were detected in JMML patients without canonical RAS pathway mutations. Genome-wide methylation analysis identified the hypermethylation profile associated with poor clinical outcome.